


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pyrrole substituted 2-indolinone having the chemical



structure:

wherein:

R¹ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, acetyl, C-amido, C-thioamido, sulfonyl and trihalomethanesulfonyl;

R² is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl and heteroalicyclic;

R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-

amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and $-NR^{11}R^{12}$;

R^{11} and R^{12} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring;

R^7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethane-sulfonyl;

R^8 and R^{10} are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, carbonyl, C-carboxy, O-carboxy, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and $-NR^{11}R^{12}$; ~~providing, however, that at least one of R^8 , R^9 or R^{10} is a group having the formula $-(alk)_iZ$; and~~

R^9 is alkyl substituted with $-NR^{11}R^{12}$ ~~substituted or unsubstituted nitrogen;~~

~~Alk_i is selected from the group consisting of alkyl, alkenyl or alkynyl; and,~~

~~Z is a polar group.~~

2. (Original) The compound of claim 1 wherein R^1 , R^2 and R^7 are hydrogen.

3. (Canceled)

4. (Previously Presented) The compound of claim 1 wherein R^3 , R^4 , R^5 and R^6 are independently selected from the group consisting of:

hydrogen;

halo;

unsubstituted lower alkyl;

lower alkyl substituted with one or more groups selected from the group consisting of:

hydroxy;

halo;

C-carboxy substituted with a group selected from the group consisting of:

hydrogen; or,

unsubstituted lower alkyl;

amino; or,

-NR¹¹R¹²;

unsubstituted lower alkyl alkoxy;

lower alkyl alkoxy substituted with one or more halo groups;

unsubstituted aryloxy;

aryloxy substituted with one or more groups independently selected from the group consisting of:

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

hydroxy;

unsubstituted lower alkyl alkoxy;

halo;

amino; or,

-NR¹¹R¹²;

S-sulfonamido wherein R¹¹ and R¹² are independently selected from the group consisting of hydrogen and unsubstituted lower alkyl;

unsubstituted aryl;

aryl substituted with one or more groups independently selected from the group consisting of:

halo;

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

unsubstituted lower alkyl alkoxy;

amino; or,

-NR¹¹R¹²;

unsubstituted heteroaryl;

heteroaryl substituted with one or more groups independently selected from the group consisting of:

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

unsubstituted lower alkyl alkoxy;

hydroxy;

halo;

amino; or,

-NR¹¹R¹²;

unsubstituted heteroalicyclic;

heteroalicyclic substituted with one or more groups independently selected from the group consisting of:

halo;

hydroxy;

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

unsubstituted lower alkyl alkoxy;

amino; or,

-NR¹¹R¹²;

unsubstituted lower alkyl O-carboxy;

C-amido wherein R¹¹ and R¹² are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl; and,

N-amido wherein R¹¹ and R¹² are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl.

5. (Previously Presented) The compound of claim 3 wherein R³, R⁴, R⁵ and R⁶ are selected from the group consisting of:

hydrogen;

halo;

unsubstituted lower alkyl;

lower alkyl substituted with one or more groups selected from the group consisting of:

hydroxy;

halo;

C-carboxy substituted with a group selected from the group consisting of:

hydrogen; or,

unsubstituted lower alkyl;

amino; or,

$-NR^{11}R^{12}$;

unsubstituted lower alkyl alkoxy;

lower alkyl alkoxy substituted with one or more halo groups;

unsubstituted aryloxy;

aryloxy substituted with one or more groups independently selected from the group consisting of:

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

hydroxy;

unsubstituted lower alkyl alkoxy;

halo;

amino; or,

$-NR^{11}R^{12}$;

S-sulfonamido wherein R¹¹ and R¹² are independently selected from the group consisting of hydrogen and unsubstituted lower alkyl;

unsubstituted aryl;

aryl substituted with one or more groups independently selected from the group consisting of:

halo;

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

unsubstituted lower alkyl alkoxy;

amino; or,

-NR¹¹R¹²;

unsubstituted heteroaryl;

heteroaryl substituted with one or more groups independently selected from the group consisting of:

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

unsubstituted lower alkyl alkoxy;

hydroxy;

halo;

amino; or,

-NR¹¹R¹²;

unsubstituted heteroalicyclic;

heteroalicyclic substituted with one or more groups independently selected from the group consisting of:

halo;

hydroxy;

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

unsubstituted lower alkyl alkoxy;

amino; or,

-NR¹¹R¹²;

unsubstituted lower alkyl O-carboxy;

C-amido wherein R¹¹ and R¹² are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl; and,

N-amido wherein R¹¹ and R¹² are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl.

Claims 6-8 (Canceled)

9. (Original) The compound of claim 2 wherein R⁷ is selected from the group consisting of:

hydrogen,

unsubstituted lower alkyl, and,

lower alkyl substituted with a group selected from the group consisting of:

unsubstituted cycloalkyl,

unsubstituted aryl, and,

aryl substituted with a group selected from hydroxy, unsubstituted lower alkyl alkoxy and halo.

10. (Original) The compound of claim 2 wherein Z is selected from the group consisting of:

$-C(=O)NR^{13}R^{14}$ wherein R^{13} and R^{14} are independently selected from the group consisting of:

hydrogen,

unsubstituted lower alkyl,

lower alkyl substituted with a group selected from the group consisting of amino and $-NR^{11}R^{12}$,

unsubstituted aryl,

aryl substituted with one or more groups selected from the group consisting of halo, hydroxy, unsubstituted lower alkyl alkoxy and trihalomethyl,

unsubstituted heteroaryl,

unsubstituted heteroalicyclic, and,

combined, a five-member or a six-member unsubstituted heteroalicyclic, and,

$-NR^{11}R^{12}$, wherein,

R^{11} and R^{12} are independently selected from the group consisting of unsubstituted lower alkyl and, combined, a five-member or a six-member unsubstituted heteroalicyclic ring.

11. (Original) The compound of claim 1 wherein:

R^7 is selected from the group consisting of unsubstituted lower alkyl,

lower alkyl substituted with one or more groups selected from the group consisting of:

unsubstituted cycloalkyl,

unsubstituted aryl,

aryl substituted with one or more groups independently selected from the group consisting of halo and unsubstituted lower alkyl alkoxy and unsubstituted lower alkyl carboxyalkyl, and,

Z is selected from the group consisting of unsubstituted C-carboxy and unsubstituted lower alkyl C-carboxy.

12. (Original) The compound of claim 1 wherein:

R^3 , R^4 , R^5 , and R^6 are independently selected from the group consisting of

hydrogen,

halo,

unsubstituted lower alkyl,

lower alkyl substituted with one or more hydroxy groups,

unsubstituted lower alkoxy,

unsubstituted aryl,

aryl substituted with one or more unsubstituted lower alkoxy groups, and,

$S(O)_2NR^{11}R^{12}$,

R^5 is hydrogen,

R^6 is $-NR^{11}R^{12}$, and,

R¹¹ and R¹² are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and, combined, a five-member or a six-member unsubstituted heteroalicyclic ring.

13. (Canceled)

14. (Canceled)

15. (Original) A pharmaceutical composition, comprising:

a compound, salt or prodrug of claim 1; and,

a physiologically acceptable carrier or excipient.

16. (Previously Presented) A method for treating a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a compound, salt or prodrug of claim 1 to said organism.

17. (Canceled)

18. (Original) The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

19. (Original) The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

20. (Original) The method of claim 16 wherein said protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

21. (Original) The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

22. (Original) The method of claim 16 wherein said organism is a human.

23. (Canceled)

24. (Previously Presented) A compound selected from the group consisting of:

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

5-Bromo-3-[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-6-phenyl-1,3-dihydroindol-2-one

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-6-(2-methoxyphenyl)-1,3-dihydroindol-2-one

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-6-(3-methoxyphenyl)-1,3-dihydroindol-2-one

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-6-(4-methoxyphenyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

5-Bromo-3-[4-(3-dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-phenyl-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-(2-methoxyphenyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-(3-methoxyphenyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-(4-methoxyphenyl)-1,3-dihydroindol-2-one

5-Chloro-3-[4-(3-dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

6-Chloro-3-[4-(3-dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-methoxy-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-methoxy-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-methyl-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-4-methyl-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-4-(2-hydroxyethyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid amide

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid isopropylamide

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-(morpholine-4-sulfonyl)-1,3-dihydroindol-2-one, and

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide.